Skip to main content
Triangle logo TriangleGet started

Biospecimen Collection (NCT06948084)

Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse: a one-minute explainerNCT069480841 min

Biospecimen Collection trial for Recurrent Multiple Myeloma (NCT06948084). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with high-risk multiple myeloma that relapsed or resisted treatment after one prior line. If previously given daratumumab or isatuximab, the myeloma must remain sensitive, with over 180 days since the last dose.

The idea: compare daratumumab plus teclistamab injections against daratumumab with dexamethasone and either pomalidomide or carfilzomib. Daratumumab targets CD38; teclistamab links T cells to BCMA-bearing myeloma cells to trigger an immune attack. Researchers measure residual disease after six cycles.

This phase 2 study plans 80 patients. ECOG-ACRIN leads; 31 US locations list recruitment.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.